A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions

被引:14
作者
Reckless, J
Rubin, EM
Verstuyft, JB
Metcalfe, JC
Grainger, DJ
机构
[1] Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England
[2] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England
[3] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA
关键词
arteries; atherosclerosis; macrophages; quantitative immunofluorescence; cytokines;
D O I
10.1159/000051054
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The introduction of a range of different genetic modifications in mice results in altered lipoprotein metabolism and the development of vascular lipid lesions. At present, however, it is unclear to what extent the molecular events underlying lipid lesion formation are similar in these different mouse models of atherosclerosis. The aim of this study was to compare the protein expression pattern of lipid lesions from seven different mouse lines with varying susceptibility to vascular lipid lesion development, to determine to what extent lesions induced by different genetic interventions have a similar composition. The proteins we have measured, using quantitative immunofluorescence, are proteins whose expression is known to be modulated during atherogenesis in humans, including plasminogen activator inhibitor (PAI)-1, transforming growth factor (TGF)-beta1, osteopontin and the macrophage marker CD11b. In all the mice lines we have investigated, PAI-1 was elevated wherever lesions developed. Active TGF-beta was depressed in the vessel wall of mice which developed lipid lesions, particularly in the intima. In contrast, TGF-beta1 antigen (active plus latent TGF-beta1) was increased at lesion sites. Accumulation of osteopontin and, with the marked exception of apolipoprotein(a) transgenic mice, tissue macrophages occurred at sites of lipid deposition in the vessel wall. Each lesion, irrespective of its size and the mouse strain in which it developed, had similar amounts of PAI-1, active TGF-P and osteopontin per unit area of lesion. These data are consistent with a common phenotype accompanying atherogenesis, irrespective of the genetic basis of susceptibility. Copyright (C) 2001 S. Karger AG. Basel.
引用
收藏
页码:256 / 265
页数:10
相关论文
共 54 条
[1]   Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity [J].
Ashkar, S ;
Weber, GF ;
Panoutsakopoulou, V ;
Sanchirico, ME ;
Jansson, M ;
Zawaideh, S ;
Rittling, SR ;
Denhardt, DT ;
Glimcher, MJ ;
Cantor, H .
SCIENCE, 2000, 287 (5454) :860-864
[2]   TRANSGENIC MOUSE MODELS OF LIPOPROTEIN METABOLISM AND ATHEROSCLEROSIS [J].
BRESLOW, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8314-8318
[3]   Mouse models of atherosclerosis [J].
Breslow, JL .
SCIENCE, 1996, 272 (5262) :685-688
[4]   Increased PAI activity and PAI-1 antigen occurring with an oral fat load:: associations with PAI-1 genotype and plasma active TGF-β levels [J].
Byrne, CD ;
Wareham, NJ ;
Martensz, ND ;
Humphries, SE ;
Metcalfe, JC ;
Grainger, DJ .
ATHEROSCLEROSIS, 1998, 140 (01) :45-53
[5]   EXPRESSION OF HUMAN APOLIPOPROTEIN-B AND ASSEMBLY OF LIPOPROTEIN(A) IN TRANSGENIC MICE [J].
CALLOW, MJ ;
STOLTZFUS, LJ ;
LAWN, RM ;
RUBIN, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2130-2134
[6]   ATHEROGENESIS IN TRANSGENIC MICE WITH HUMAN APOLIPOPROTEIN-B AND LIPOPROTEIN (A) [J].
CALLOW, MJ ;
VERSTUYFT, J ;
TANGIRALA, R ;
PALINSKI, W ;
RUBIN, EM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (03) :1639-1646
[7]  
DEBONO D, 1994, BRIT HEART J, V71, P504
[8]   Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated [J].
Diebold, RJ ;
Eis, MJ ;
Yin, MY ;
Ormsby, I ;
Boivin, GP ;
Darrow, BJ ;
Saffitz, JE ;
Doetschman, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (26) :12215-12219
[9]   Cytokine expression in advanced human atherosclerotic plaques:: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines [J].
Frostegård, J ;
Ulfgren, AK ;
Nyberg, P ;
Hedin, U ;
Swedenborg, J ;
Andersson, U ;
Hansson, GK .
ATHEROSCLEROSIS, 1999, 145 (01) :33-43
[10]  
GAMBLE JR, 1993, J IMMUNOL, V150, P4494